Lately, non-medical application of prescription drugs has turned out be one of the grave matter of concern for public health. This is due to growing prevalence and increasing mortality as a result of same in the U.S.
According to the report published by the National Institute of Drug Abuse (NIDA), approximately 52 million people have found to use prescription drugs for non-medical purpose once in their lifetime. In addition, pain reliever OxyContin and Vicodin are prominently abused drugs among youth.
Use of wrong prescription drugs and addiction to prescription drugs have resulted in large cases of comorbid illness among geriatric population. Consistent upward slope of abuse of prescription drugs is anticipated to propel drugs of abuse testing market between 2018 and 2026.
Individuals involved in use of illicit drugs are likely to be less productive, more frequently involved in a workplace accident, and change jobs abruptly. As a result, employers emphasize on regulating their employees against drugabstinence through regular drugs of abuse tests.
This, in turn, is anticipated to fuel demand for drug abuse testing for both public and private employers in the tenure of forecast period.
As per a report published by Transparency Market Research on the global drugs of abuse testing market for the forecast period 2019-2027, the market is estimated to scale at a moderate CAGR of 5.7% in the forecast period.
Law Enforcement Agencies Emphasize Testing for Drugs of Abuse
The global drugs of abuse testing market is driven by rise in the consumption of illicit drugs, which in turn in creating demand for drug abuse tests. In addition, growth of the market is ascribed to high demand for drugs of abused testing and screening products from law enforcement agencies.
Meanwhile, rise in number of clinic bases diagnostic laboratories providing drugs of abuse testing services has been extensively contributing to the market growth. In addition, substantial rise in number of hospital-based laboratories, physician laboratories, and independent laboratories and retail for sample collection has been recorded in past few years. These laboratories are offering sample collection and tests in order to screen various drugs. This, in turn, is anticipated to boost growth of the drug of abuse testing market.
For example, Centers for Medicare and Medicaid Services and Department of Health and Human Services have provided an estimation regarding number of clinical laboratories in the U.S. In the year 2015, 137,000 clinical laboratories were present in the US alone. Moving forward, the number of clinic is projected to increase during the forecast period, owing to on-going developments in the diagnostic industry and high availability of low-cost equipment.
Aforementioned factors are likely to aid to further improvement in the global drugs of abuse testing market and in formulation of further growth strategies by companies in the market.
Some of the key companies operating in the global drugs of abuse testing market are Drägerwerk AG & Co. KGAA, Abbott Laboratories,CannAmm, Hoffmann-La Roche AG, OraSure, Biorad Laboratories, Inc., Siemens AG, Alfa Scientific Designs, Thermo Fisher Scientific Inc., Omega Laboratories, Danaher Corporation, Premier Biotech, Lifeloc, MPD, Inc., Shimadzu, Psychemedics, SureHire, Quest Diagnostics Incorporated, and Express Diagnostics International Inc.
To Get an Exhaustive Overview about the Competition in Drugs of Abuse Testing Market, Request for a Report Brochure a https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=54426
Poor Healthcare Infrastructure Restrains Growth of Drugs of Abuse Testing Market
On the other hand, low awareness, inadequate social support, and poverty have augmented consumption rate of illicit drugs in developing counties of Africa, Asia Pacific, and Latin America. Hence, the drugs of abuse testing market is likely to witness mild growth rate in these regions.
For instance, as per statistic provided by the WHO, 77% of children in Brazil are found to consume alcohol on a regular basis.
Further, inadequate healthcare infrastructure for drug testing services are anticipated to interfere with growth of the drugs of abuse testing market in developing and low income countries
